drugset / Trial / NCT02173574

Two-way Interaction Between Alisporivir and EDP239

NCT02173574

Phase 1 Completed 42 enrolled Enanta Pharmaceuticals, Inc
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients. The purpose of Part 2 is to inform the drug-drug interaction potential of EDP239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in Part 1, if observed.

Timeline

Start
2014-08
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisporivir Protein / enzyme biologic
Subject EDP239 Unknown